Latest Biotech News

Tubulis closed a €308 million (≈$356 million) Series C — one of Europe’s largest biotech rounds this year — to advance its next‑generation antibody‑drug conjugates (ADCs), notably TUB‑040 in...

Pacific Biosciences announced plans to allow reuse of its most expensive consumables and rolled out Sprq‑Nx chemistry to boost output, targeting sub‑$300 per genome costs for large projects. The...

Lonza received Swissmedic approval for a new aseptic filling line in Stein capable of handling highly potent biologics and ADCs, expanding its drug product footprint and containment capabilities....

Create Medicines (formerly Myeloid Therapeutics) announced a strategic rebrand and expanded its in‑vivo mRNA‑LNP immune programming platform beyond myeloid cells to include T and NK cell...

BioNTech secured up to €95 million from two EU bodies to support construction of an mRNA vaccine facility in Kigali, Rwanda, advancing regional vaccine production capacity in Africa. The funding...

Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly dual‑target metabolic injection positioned against Eli Lilly’s obesity...

Novo Nordisk agreed a development and commercialization deal giving it global rights to zaltenibart, an Omeros MASP‑3 antibody, with up to $2.1 billion in payments tied to milestones. Novo will...

Tubulis closed one of Europe’s largest Series C rounds—raising €308 million (reported variously as ~$356–361 million)—to advance its clinical‑stage antibody‑drug conjugate (ADC) portfolio and...

Lonza announced Swissmedic has granted GMP approval for its new aseptic drug‑product filling line in Stein, Switzerland, enabling contained manufacturing of highly potent biologics including ADCs....

Researchers published DeepSomatic, a deep‑learning platform that improves somatic small‑variant detection across short‑ and long‑read sequencing technologies, and released a set of public...

Google’s C2S‑Scale 27B foundation model, developed with Yale and based on Gemma, generated a novel hypothesis identifying an interferon‑conditional amplifier that could boost antigen presentation...

Tempus entered a multi‑year collaboration with Whitehawk Therapeutics to apply Tempus’ de‑identified multimodal real‑world database to guide biomarker discovery and indication prioritization...

Pelage Pharmaceuticals closed a $120 million Series B to finance a Phase III program for PP‑405, a topical small molecule designed to activate dormant hair‑follicle stem cells. Investors included...

Adcytherix announced a €104 million Series A to propel its lead antibody‑drug conjugate program toward first‑in‑human studies. The French biotech raised the financing from institutional...

Merck KGaA’s MilliporeSigma announced a definitive agreement to acquire the chromatography business of JSR Life Sciences, broadening its downstream processing portfolio with JSR’s Protein A resins...

Novo Nordisk agreed to acquire global rights to zaltenibart from Omeros in a deal that pays Omeros $340 million upfront and could reach $2.1 billion with milestones. The antibody inhibits MASP‑3,...

Tubulis closed a €308 million (about $356 million) Series C to accelerate clinical development of its antibody‑drug conjugate portfolio, led by lead candidate TUB‑040. The round is among the...

Pelage Pharmaceuticals raised $120 million in an oversubscribed Series B to support a phase III program for PP‑405, a topical small molecule designed to activate dormant hair‑follicle stem cells....

Kailera Therapeutics secured $600 million in a Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable targeting the same receptors as existing dual‑agonist obesity...

The U.S. Department of Health and Human Services awarded Tempus AI a roughly $60 million ARPA‑H contract to provide testing and research services aimed at developing biomarker‑driven adaptive...